Teplizumab
Teplizumab
Teplizumab (pronounced as Tep-li-zu-mab) is a monoclonal antibody designed for the treatment of Type 1 diabetes. It is an experimental drug that has shown promise in delaying the onset of the disease in high-risk individuals.
Etymology
The name "Teplizumab" is derived from the generic naming system for therapeutic monoclonal antibodies, where "-mab" signifies it as a monoclonal antibody, and "tepli-" is a unique prefix.
Mechanism of Action
Teplizumab works by targeting CD3, a molecule found on the surface of T cells, which are a type of white blood cell involved in the immune response. By binding to CD3, Teplizumab modulates the immune system's response, preventing it from attacking the insulin-producing beta cells in the pancreas.
Clinical Trials
Teplizumab has undergone several clinical trials to assess its safety and efficacy in preventing or delaying the onset of Type 1 diabetes. The results have been promising, with high-risk individuals showing a delay in disease onset of approximately two years.
Related Terms
External links
- Medical encyclopedia article on Teplizumab
- Wikipedia's article - Teplizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski